FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004011018> ?p ?o ?g. }

• W2004011018 endingPage "1748" @default.
• W2004011018 startingPage "1742" @default.
• W2004011018 abstract "Combination epigenetic treatment (EGT) utilizing DNA methyl transferase inhibitors (DNMTi) and histone deacetylase inhibitors (HDACi) may be more efficacious than single agent treatment in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The molecular mechanisms behind the potential clinical efficacy of combination EGT treatment are incompletely understood and the frequently lengthy EGT regimes required to determine clinical response have generated a significant demand for early molecular markers of treatment response. Our study aimed to identify the effect of combination azacitidine (AZA) and panobinostat (LBH589) on expression levels of a panel of genes implicated in the pathogenesis of high-risk MDS or AML in HL-60 cells. We also characterized gene expression profiles in peripheral blood mononuclear (PBMCs) from patients in a recently reported phase Ib/II clinical trial using the combination of AZA and LBH589 and correlated these findings with clinical response to treatment. In vitro analysis demonstrated increased expression of caspase-3, Nor-1, NUR77, p15INK4B and p21WAF1/CIP1 and decreased expression of Bcl‑xL in HL-60 cells treated with combination EGT. Analysis of patient samples prior to treatment demonstrated a significant reduction in NUR77 and p21WAF1/CIP1 expression compared to healthy controls. NUR77 and p21WAF1/CIP1 levels were similar between treatment non‑responders and responders at screening. Early post first cycle treatment (day 25) analysis demonstrated a significant increase in expression of both NUR77, and p21WAF1/CIP1. A significant increase in NUR77, and p21WAF1/CIP1 together with a trend to increase in p15INK4B first cycle expression was observed in treatment responders compared to non-responders. In summary, combination AZA and LBH589 epigenetic treatment is associated with in vitro and in vivo modulation of genes implicated in the pathogenesis of MDS/AML. Early expression of NUR77 and p21WAF1/CIP1 correlated with clinical response to combination EGT suggesting investigation for potential use as molecular markers of early treatment response may be warranted." @default.
• W2004011018 created "2016-06-24" @default.
• W2004011018 creator A5002073335 @default.
• W2004011018 creator A5043972467 @default.
• W2004011018 creator A5045994438 @default.
• W2004011018 creator A5065500318 @default.
• W2004011018 creator A5080952412 @default.
• W2004011018 date "2014-07-22" @default.
• W2004011018 modified "2023-10-16" @default.
• W2004011018 title "Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies" @default.
• W2004011018 cites W1484293540 @default.
• W2004011018 cites W1966010937 @default.
• W2004011018 cites W1967018540 @default.
• W2004011018 cites W1970772467 @default.
• W2004011018 cites W1973042221 @default.
• W2004011018 cites W1974277276 @default.
• W2004011018 cites W1978375723 @default.
• W2004011018 cites W1981353115 @default.
• W2004011018 cites W1989336886 @default.
• W2004011018 cites W2005205763 @default.
• W2004011018 cites W2022733644 @default.
• W2004011018 cites W2030500261 @default.
• W2004011018 cites W2038987009 @default.
• W2004011018 cites W2043033879 @default.
• W2004011018 cites W2046091686 @default.
• W2004011018 cites W2046921388 @default.
• W2004011018 cites W2086990980 @default.
• W2004011018 cites W2089111728 @default.
• W2004011018 cites W2102650381 @default.
• W2004011018 cites W2104337841 @default.
• W2004011018 cites W2118771330 @default.
• W2004011018 cites W2129510594 @default.
• W2004011018 cites W2133653334 @default.
• W2004011018 cites W2155235678 @default.
• W2004011018 cites W2155842772 @default.
• W2004011018 cites W2156134411 @default.
• W2004011018 cites W2163583950 @default.
• W2004011018 cites W2166506757 @default.
• W2004011018 cites W2354344320 @default.
• W2004011018 doi "https://doi.org/10.3892/ijo.2014.2555" @default.
• W2004011018 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25051119" @default.
• W2004011018 hasPublicationYear "2014" @default.
• W2004011018 type Work @default.
• W2004011018 sameAs 2004011018 @default.
• W2004011018 citedByCount "5" @default.
• W2004011018 countsByYear W20040110182017 @default.
• W2004011018 countsByYear W20040110182018 @default.
• W2004011018 countsByYear W20040110182019 @default.
• W2004011018 crossrefType "journal-article" @default.
• W2004011018 hasAuthorship W2004011018A5002073335 @default.
• W2004011018 hasAuthorship W2004011018A5043972467 @default.
• W2004011018 hasAuthorship W2004011018A5045994438 @default.
• W2004011018 hasAuthorship W2004011018A5065500318 @default.
• W2004011018 hasAuthorship W2004011018A5080952412 @default.
• W2004011018 hasBestOaLocation W20040110181 @default.
• W2004011018 hasConcept C104317684 @default.
• W2004011018 hasConcept C121608353 @default.
• W2004011018 hasConcept C126322002 @default.
• W2004011018 hasConcept C137061746 @default.
• W2004011018 hasConcept C150194340 @default.
• W2004011018 hasConcept C190727270 @default.
• W2004011018 hasConcept C202751555 @default.
• W2004011018 hasConcept C203014093 @default.
• W2004011018 hasConcept C2776202225 @default.
• W2004011018 hasConcept C2776239401 @default.
• W2004011018 hasConcept C2776999253 @default.
• W2004011018 hasConcept C2778305200 @default.
• W2004011018 hasConcept C2778729363 @default.
• W2004011018 hasConcept C2779282312 @default.
• W2004011018 hasConcept C2780007613 @default.
• W2004011018 hasConcept C2780225316 @default.
• W2004011018 hasConcept C2780737395 @default.
• W2004011018 hasConcept C2780817109 @default.
• W2004011018 hasConcept C2781018059 @default.
• W2004011018 hasConcept C29537977 @default.
• W2004011018 hasConcept C41091548 @default.
• W2004011018 hasConcept C502942594 @default.
• W2004011018 hasConcept C54355233 @default.
• W2004011018 hasConcept C64927066 @default.
• W2004011018 hasConcept C67082663 @default.
• W2004011018 hasConcept C71924100 @default.
• W2004011018 hasConcept C86803240 @default.
• W2004011018 hasConcept C98274493 @default.
• W2004011018 hasConceptScore W2004011018C104317684 @default.
• W2004011018 hasConceptScore W2004011018C121608353 @default.
• W2004011018 hasConceptScore W2004011018C126322002 @default.
• W2004011018 hasConceptScore W2004011018C137061746 @default.
• W2004011018 hasConceptScore W2004011018C150194340 @default.
• W2004011018 hasConceptScore W2004011018C190727270 @default.
• W2004011018 hasConceptScore W2004011018C202751555 @default.
• W2004011018 hasConceptScore W2004011018C203014093 @default.
• W2004011018 hasConceptScore W2004011018C2776202225 @default.
• W2004011018 hasConceptScore W2004011018C2776239401 @default.
• W2004011018 hasConceptScore W2004011018C2776999253 @default.
• W2004011018 hasConceptScore W2004011018C2778305200 @default.
• W2004011018 hasConceptScore W2004011018C2778729363 @default.
• W2004011018 hasConceptScore W2004011018C2779282312 @default.
• W2004011018 hasConceptScore W2004011018C2780007613 @default.

• next